search
Back to results

Adolescents With COVID-19/MIS-C at HCFMUSP

Primary Purpose

Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome)

Status
Unknown status
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Home-based exercise training
Sponsored by
University of Sao Paulo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Covid19 focused on measuring Covid19, Children, Adolescents

Eligibility Criteria

7 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • school-age children and adolescents diagnosed with COVID-19

Exclusion Criteria:

  • school-age children and adolescents with MIS-C, who present: myocardial dysfunction, refractory cardiac arrhythmias, coronary artery aneurysms with or without thrombi, electrocardiographic alterations suggestive of myocardial infarction or ischemia and clinical signs of heart failure;
  • presence of any limitation or physical disability that prevents the practice of exercise;
  • pregnancy.

Sites / Locations

  • Hospital das Clinicas Faculdade de Medicina USP

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Exercise training

Control

Arm Description

A 12 weeks parallel-group randomized controlled trial will be performed, in which covid-19 survivors adolescents will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength and aerobic exercises

The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.

Outcomes

Primary Outcome Measures

Quality of Life assessed by the Pediatric Quality of Life Inventory (Peds-QoL)
The instrument was translated and validated for the Brazilian population
Quality of Life assessed by the Pediatric Quality of Life Inventory (Peds-QoL)
The instrument was translated and validated for the Brazilian population

Secondary Outcome Measures

Flow-volume loop assessed by spirometry
Aims to investigate the mechanisms that lead to dyspnea and, consequently, intolerance to physical effort
Health-related quality of life assessed by the Pediatric Outcomes Data Collection Instrument
It will also be assessed for school-age children (7-10 years old) and adolescents (11-18 years old) and by their primary caregiver
Complete blood count (hemoglobin, leukocyte, lymphocyte and platelet count)
Inflammatory markers (C-reactive protein, fibrinogen, D-dimer and ferritin);
Lactate dehydrogenase
Aspartate and alanine aminotransferase
Serum urea and creatinine
Triglycerides
Creatinine phosphokinase (CK)
Amilase
Lipase
Troponin T
Pro-BNP
Lung abnormalities will be assessed by pulmonary computed tomography
Patchy ground-glass opacities, crazy-paving pattern, and localization and pattern of large, confluent or small nodular lesions will be assessed
Systolic and diastolic function will be assessed by echocardiogram
Conventional transthoracic echocardiogram with color Doppler to assess systolic and diastolic function
Valve dysfunction will be assessed by echocardiogram
Conventional transthoracic echocardiogram with color Doppler to search for valve dysfunction
Pericardial effusion will be assessed by echocardiogram
Conventional transthoracic echocardiogram with color Doppler to search for pericardial effusion
Coronary arteries will be assessed by echocardiogram
Conventional transthoracic echocardiogram with color Doppler to search for aspects of the coronary arteries
Ischemia will be assessed by echocardiogram
Echocardiogram with two-dimensional speckle-tracking technique to identify subclinical changes suggestive of ischemia or myocarditis
Immunocompetence, including thymic function
Baseline levels of cytokines IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-y, and IL-17A in serum samples will be tested by flow cytometry using the CBA technique (Cytometric bead array, BD Biosciences)
Leukogram will be assessed by leukocyte and lymphocyte counts
Immunophenotyping of lymphocytes T cell lineages will be evaluated by flow cytometry
T cell lineages: CD3CD4, CD3CD8, naive cells (CD45RA+), memory cells (CD45RA-), effector cells (CD38+HLADR+)
Immunophenotyping of lymphocytes B cell lineages will be evaluated by flow cytometry
B cell lineages: CD19, naive cells (CD27-), memory cells (CD27+), plasmablasts (CD27+CD38+CD138-), (plasmocytes CD27+CD38+CD138+)
Immunophenotyping of lymphocytes NK cells will be evaluated by flow cytometry
NK cells: (CD3-CD16+CD56+), degranulated: CD107a+
Serum levels of anti-Streptococcus pneumoniae IgG antibodies
Anti-pneumococcal vaccine response will be assessed by ELISA
The antipneumococcal antibody titer against 6 polysaccharides (serotypes 1, 5, 6B, 9V, 14, and 18C) will be analyzed by ELISA. The seroconversion criteria is IgG values > 1.3 mg/mL for each polysaccharide assessed
Evaluation of the thymus by the determination of TRECs (Thymic recent emigrant cells or T-cell receptor excision circles)
TRECs evaluate the peripheral function of the thymus from cells that have recently been released, using the RT-PCR technique
Changes in frequency of the autoantibodies of the thyroid gland
(anti-thyroperoxidase antibodies, anti-thyroglobulin)
Changes in frequency of the anti-GAD antibody will be assessed using immunoprecipitation
Changes in frequency of the anti-islet antibody of Langerhans will be assessed using indirect fluorescence
Changes in frequency of the anti-insulin antibody will be assessed by radioimmunoassay
Diagnosis of thyroid dysfunction will be assessed by thyroid profile (TSH, free T4 and T3)
Diagnosis of type 1 diabetes mellitus will be assessed by the metabolic profile (fasting glucose, glycated hemoglobin and C peptide)
Linear growth will be assessed by using a standardized stadiometer, calculating standard deviation, growth curves, and growth speed
Development of puberty will be assessed according to the criteria of Tanner and Marshall in adolescents in the prepubertal age group
Bone age will be assessed using non-dominant hand and wrist radiography
Bone mineral density will be assessed by Bone densitometry (DXA) in the region of the lumbar spine
Bone mineral content will be assessed by Bone densitometry (DXA) in the region of the lumbar spine
Bone mineral density will be assessed by Bone densitometry (DXA) in the proximal femur
Bone mineral content will be assessed by Bone densitometry (DXA) in the proximal femur
Bone mineral density will be assessed by Bone densitometry (DXA) in the whole body
Bone mineral content will be assessed by Bone densitometry (DXA) in the whole body
Body composition (visceral adipose tissue) will be assessed by Bone densitometry
Body composition (lean mass) will be assessed by Bone densitometry
Body composition (fat mass) will be assessed by Bone densitometry
Bone biochemical and bone remodeling markers (calcium, phosphorus, 25OH alkaline phosphatase vitamin D, PTH, CTX, P1NP)
Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk used during the "timed up and go" test
Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk during the 6-minute walk test
Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk during the 10 meter gait test
Pediatric gait assessment will be assessed by musculoskeletal ultrasound
Genetic Polymorphism Analysis will be assessed by salting out methodology followed by q-PCR (Real-time PCR) using the TaqMan assay using Step One Plus equipment
According to the gene sequence studied, the analysis will be performed using the Sanger sequencing technique with capillary electrophoresis in a 3130 automatic sequencer (Applied Biosystems). The genetic polymorphisms of the ABO system gene (rs505922), two polymorphisms of the OPRM1 gene (rs1799971 and rs1799972) and a polymorphism of the BDNF gene (rs6265) will be investigated, with possible contributions to the risk of impaired gait.
Mental health will be assessed by the "Strengths and Weaknesses of Attention-deficit/hyperactivity disorder (ADHD) symptoms and Normal behaviors"
This is an 18-item parent questionnaire for children and adolescents (18 years and younger). This rating scale includes positive "weaknesses" and negative "strengths" scoring, assessing symptoms of Attention-Deficit/Hyperactivity Disorder. Parents are asked to compare their child's behavior in a variety of settings over the past month to other children on a 7-point: 3-Far below, 2-Below, 1-Slightly below, 0-Average, -1-Slightly average, -2-Above, -3-Far above. Higher scores indicate greater symptomology
Mental health will be assessed by the "Strengths and Difficulties Questionnaire"
The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire, and includes 25 items on psychological attribute: emotional symptoms (5 items), conduct problems (5 items) hyperactivity/inattention (5 items), peer relationship problems (5 items), prosocial behaviour (5 items). Higher scores indicate greater difficulties
Mental health will be assessed by the "Depression, Anxiety and Stress Scale"
The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress (7 items each subscale). Patients are asked to score every item on a scale from 0 (did not apply to me at all) to 3 (applied to me very much). Sum scores for the total DASS-total scale range between 0 and 120. Scores ≥60 (for DASS-total) and ≥21 (for the depression subscale) are labeled as "high" or "severe".
Physical activity levels assessed by ActivPAL
ActivPAL will be used for 7 days for at least 10 hours/day
Food consumption levels assessed by food records
24-hour recalls will be assessed on three non-consecutive days (two weekdays, and one weekend). Online Dietbox will be used.
Blood flow will be assessed using a Doppler Ultrasound
Baseline blood flow measurements will be assessed in the brachial artery
Endothelial function will be assessed using a Doppler Ultrasound
Flow-mediated vasodilation (VMF) will be assessed in the brachial artery

Full Information

First Posted
December 1, 2020
Last Updated
December 8, 2020
Sponsor
University of Sao Paulo
Collaborators
Hospital das Clínicas da Faculdade de Medicina da USP, Fundação de Amparo à Pesquisa do Estado de São Paulo
search

1. Study Identification

Unique Protocol Identification Number
NCT04659486
Brief Title
Adolescents With COVID-19/MIS-C at HCFMUSP
Official Title
Prospective Studies in School-aged Children and Adolescents With COVID-19 Treated at HCFMUSP
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 24, 2020 (Actual)
Primary Completion Date
April 30, 2021 (Anticipated)
Study Completion Date
April 30, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Sao Paulo
Collaborators
Hospital das Clínicas da Faculdade de Medicina da USP, Fundação de Amparo à Pesquisa do Estado de São Paulo

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a protocol aimed at children and adolescents contaminated with COVID, treated at the Hospital das Clínicas, University of Sao Paulo, Brazil (HCFMUSP), in the recovery phase. The study aims to evaluate the spectrum of pathogenic lesions of the virus not only in the respiratory system, but digestive, immunological, neurological and others. Clinical, evolutionary, laboratory and functional parameters will be used.
Detailed Description
School-age children and adolescents COVID-19 survivors may have persistent inflammation, a chronic course of COVID-19, with isolated or concomitant aggressions of various organs and systems, making this disease a potential chronic condition, impacting aspects of quality of life related to health (HRQoL), physical and mental health. In addition, pediatric COVID-19 can induce autoimmunity (with the possibility of primary hypothyroidism and type I diabetes mellitus), delayed linear growth and delayed pubertal development, secondary immunodeficiency and present genetic polymorphisms in brain plasticity impacting rehabilitation. School-aged children and adolescents with COVID-19 could present muscle weakness, dysautonomy, asthenia and physical inactivity, so it is essential that safe and effective interventions are developed to maintain adequate levels of physical activity and that they can be implemented on a large scale. However, to date, there are no systematic longitudinal studies that have evaluated all these aspects in a pediatric population that survived COVID-19, particularly with chronic conditions and who were hospitalized in a tertiary service.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection
Keywords
Covid19, Children, Adolescents

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Exercise training
Arm Type
Experimental
Arm Description
A 12 weeks parallel-group randomized controlled trial will be performed, in which covid-19 survivors adolescents will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength and aerobic exercises
Arm Title
Control
Arm Type
No Intervention
Arm Description
The control group will receive all regular medical care and advice on healthy lifestyle including the promotion of recommended physical activity levels.
Intervention Type
Behavioral
Intervention Name(s)
Home-based exercise training
Intervention Description
Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
Primary Outcome Measure Information:
Title
Quality of Life assessed by the Pediatric Quality of Life Inventory (Peds-QoL)
Description
The instrument was translated and validated for the Brazilian population
Time Frame
Change from Baseline at 3 months
Title
Quality of Life assessed by the Pediatric Quality of Life Inventory (Peds-QoL)
Description
The instrument was translated and validated for the Brazilian population
Time Frame
Change from Baseline at 6 months
Secondary Outcome Measure Information:
Title
Flow-volume loop assessed by spirometry
Description
Aims to investigate the mechanisms that lead to dyspnea and, consequently, intolerance to physical effort
Time Frame
Baseline, 3 months, 6 months
Title
Health-related quality of life assessed by the Pediatric Outcomes Data Collection Instrument
Description
It will also be assessed for school-age children (7-10 years old) and adolescents (11-18 years old) and by their primary caregiver
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Complete blood count (hemoglobin, leukocyte, lymphocyte and platelet count)
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Inflammatory markers (C-reactive protein, fibrinogen, D-dimer and ferritin);
Time Frame
Baseline, 3 months, 6 months,12 months
Title
Lactate dehydrogenase
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Aspartate and alanine aminotransferase
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Serum urea and creatinine
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Triglycerides
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Creatinine phosphokinase (CK)
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Amilase
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Lipase
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Troponin T
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Pro-BNP
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Lung abnormalities will be assessed by pulmonary computed tomography
Description
Patchy ground-glass opacities, crazy-paving pattern, and localization and pattern of large, confluent or small nodular lesions will be assessed
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Systolic and diastolic function will be assessed by echocardiogram
Description
Conventional transthoracic echocardiogram with color Doppler to assess systolic and diastolic function
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Valve dysfunction will be assessed by echocardiogram
Description
Conventional transthoracic echocardiogram with color Doppler to search for valve dysfunction
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Pericardial effusion will be assessed by echocardiogram
Description
Conventional transthoracic echocardiogram with color Doppler to search for pericardial effusion
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Coronary arteries will be assessed by echocardiogram
Description
Conventional transthoracic echocardiogram with color Doppler to search for aspects of the coronary arteries
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Ischemia will be assessed by echocardiogram
Description
Echocardiogram with two-dimensional speckle-tracking technique to identify subclinical changes suggestive of ischemia or myocarditis
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Immunocompetence, including thymic function
Description
Baseline levels of cytokines IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-y, and IL-17A in serum samples will be tested by flow cytometry using the CBA technique (Cytometric bead array, BD Biosciences)
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Leukogram will be assessed by leukocyte and lymphocyte counts
Time Frame
Baseline, 3 months, 6 months,, 12 months
Title
Immunophenotyping of lymphocytes T cell lineages will be evaluated by flow cytometry
Description
T cell lineages: CD3CD4, CD3CD8, naive cells (CD45RA+), memory cells (CD45RA-), effector cells (CD38+HLADR+)
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Immunophenotyping of lymphocytes B cell lineages will be evaluated by flow cytometry
Description
B cell lineages: CD19, naive cells (CD27-), memory cells (CD27+), plasmablasts (CD27+CD38+CD138-), (plasmocytes CD27+CD38+CD138+)
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Immunophenotyping of lymphocytes NK cells will be evaluated by flow cytometry
Description
NK cells: (CD3-CD16+CD56+), degranulated: CD107a+
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Serum levels of anti-Streptococcus pneumoniae IgG antibodies
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Anti-pneumococcal vaccine response will be assessed by ELISA
Description
The antipneumococcal antibody titer against 6 polysaccharides (serotypes 1, 5, 6B, 9V, 14, and 18C) will be analyzed by ELISA. The seroconversion criteria is IgG values > 1.3 mg/mL for each polysaccharide assessed
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Evaluation of the thymus by the determination of TRECs (Thymic recent emigrant cells or T-cell receptor excision circles)
Description
TRECs evaluate the peripheral function of the thymus from cells that have recently been released, using the RT-PCR technique
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Changes in frequency of the autoantibodies of the thyroid gland
Description
(anti-thyroperoxidase antibodies, anti-thyroglobulin)
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Changes in frequency of the anti-GAD antibody will be assessed using immunoprecipitation
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Changes in frequency of the anti-islet antibody of Langerhans will be assessed using indirect fluorescence
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Changes in frequency of the anti-insulin antibody will be assessed by radioimmunoassay
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Diagnosis of thyroid dysfunction will be assessed by thyroid profile (TSH, free T4 and T3)
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Diagnosis of type 1 diabetes mellitus will be assessed by the metabolic profile (fasting glucose, glycated hemoglobin and C peptide)
Time Frame
Baseline, 3 months, 6 months,, 12 months
Title
Linear growth will be assessed by using a standardized stadiometer, calculating standard deviation, growth curves, and growth speed
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Development of puberty will be assessed according to the criteria of Tanner and Marshall in adolescents in the prepubertal age group
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Bone age will be assessed using non-dominant hand and wrist radiography
Time Frame
Baseline, 12 months
Title
Bone mineral density will be assessed by Bone densitometry (DXA) in the region of the lumbar spine
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Bone mineral content will be assessed by Bone densitometry (DXA) in the region of the lumbar spine
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Bone mineral density will be assessed by Bone densitometry (DXA) in the proximal femur
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Bone mineral content will be assessed by Bone densitometry (DXA) in the proximal femur
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Bone mineral density will be assessed by Bone densitometry (DXA) in the whole body
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Bone mineral content will be assessed by Bone densitometry (DXA) in the whole body
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Body composition (visceral adipose tissue) will be assessed by Bone densitometry
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Body composition (lean mass) will be assessed by Bone densitometry
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Body composition (fat mass) will be assessed by Bone densitometry
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Bone biochemical and bone remodeling markers (calcium, phosphorus, 25OH alkaline phosphatase vitamin D, PTH, CTX, P1NP)
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk used during the "timed up and go" test
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk during the 6-minute walk test
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Pediatric gait assessment will be assessed by an Actigraph (3D accelerometer) model G-Walk during the 10 meter gait test
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Pediatric gait assessment will be assessed by musculoskeletal ultrasound
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Genetic Polymorphism Analysis will be assessed by salting out methodology followed by q-PCR (Real-time PCR) using the TaqMan assay using Step One Plus equipment
Description
According to the gene sequence studied, the analysis will be performed using the Sanger sequencing technique with capillary electrophoresis in a 3130 automatic sequencer (Applied Biosystems). The genetic polymorphisms of the ABO system gene (rs505922), two polymorphisms of the OPRM1 gene (rs1799971 and rs1799972) and a polymorphism of the BDNF gene (rs6265) will be investigated, with possible contributions to the risk of impaired gait.
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Mental health will be assessed by the "Strengths and Weaknesses of Attention-deficit/hyperactivity disorder (ADHD) symptoms and Normal behaviors"
Description
This is an 18-item parent questionnaire for children and adolescents (18 years and younger). This rating scale includes positive "weaknesses" and negative "strengths" scoring, assessing symptoms of Attention-Deficit/Hyperactivity Disorder. Parents are asked to compare their child's behavior in a variety of settings over the past month to other children on a 7-point: 3-Far below, 2-Below, 1-Slightly below, 0-Average, -1-Slightly average, -2-Above, -3-Far above. Higher scores indicate greater symptomology
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Mental health will be assessed by the "Strengths and Difficulties Questionnaire"
Description
The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire, and includes 25 items on psychological attribute: emotional symptoms (5 items), conduct problems (5 items) hyperactivity/inattention (5 items), peer relationship problems (5 items), prosocial behaviour (5 items). Higher scores indicate greater difficulties
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Mental health will be assessed by the "Depression, Anxiety and Stress Scale"
Description
The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress (7 items each subscale). Patients are asked to score every item on a scale from 0 (did not apply to me at all) to 3 (applied to me very much). Sum scores for the total DASS-total scale range between 0 and 120. Scores ≥60 (for DASS-total) and ≥21 (for the depression subscale) are labeled as "high" or "severe".
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Physical activity levels assessed by ActivPAL
Description
ActivPAL will be used for 7 days for at least 10 hours/day
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Food consumption levels assessed by food records
Description
24-hour recalls will be assessed on three non-consecutive days (two weekdays, and one weekend). Online Dietbox will be used.
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Blood flow will be assessed using a Doppler Ultrasound
Description
Baseline blood flow measurements will be assessed in the brachial artery
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Endothelial function will be assessed using a Doppler Ultrasound
Description
Flow-mediated vasodilation (VMF) will be assessed in the brachial artery
Time Frame
Baseline, 3 months, 6 months, 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: school-age children and adolescents diagnosed with COVID-19 Exclusion Criteria: school-age children and adolescents with MIS-C, who present: myocardial dysfunction, refractory cardiac arrhythmias, coronary artery aneurysms with or without thrombi, electrocardiographic alterations suggestive of myocardial infarction or ischemia and clinical signs of heart failure; presence of any limitation or physical disability that prevents the practice of exercise; pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clovis Silva, PhD
Organizational Affiliation
University of Sao Paulo
Official's Role
Study Director
Facility Information:
Facility Name
Hospital das Clinicas Faculdade de Medicina USP
City
Sao Paulo
State/Province
SP
Country
Brazil

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Adolescents With COVID-19/MIS-C at HCFMUSP

We'll reach out to this number within 24 hrs